News
-
-
-
PRESS RELEASE
Exxel Pharma Provides Business Overview and Upcoming Milestones
Exxel Pharma provided a business overview of its lead program, EX937, an innovative small molecule for treating refractory chronic cough, a condition currently with no FDA-approved therapies. The program demonstrates a differentiated approach with preclinical efficacy and safety, aiming for potential value-driving milestones in 2024 and addressing a large underserved market. The company expects EX937 to have a significant impact on improving the quality of life for adults suffering from chronic cough, with potential broad clinical applications and commercial opportunities. -
-
Buildout, Inc. Unveils Game-Changing Technology Stack including an AI-Enabled Mobile App
-
Heal and Find Hope After a Friendship Breakup in When Best Friends Aren't Forever by Kristen Reed, Out Now
-
Viking Capital Announces Closing of Latest 268 Acquisition in Atlanta
-
Aflac: 6 Common Myths About Supplemental Insurance
-
Gabriel Resources Ltd. Initial Closing of Private Placement
-
Dalata Hotel Group PLC: HOL-Holding(s) in Company*
-
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
-
M&G Credit Income Investment Trust plc: Net Asset Value(s)
-
Funding Circle Plc: POS-Transaction in Own Shares
-
Explore Copenhagen's Culinary Gem: Khun Juk Oriental, Winner of the 2023 Thai Select Signature Award and Esteemed Taittinger Ambassador
-
VOGO : French National Handball League chooses VOGO to referee the French men’s championship (“Liqui Moly Starligue”).
-
ENGIE Q1 2024 Financial Information
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2024